On the Radar: Five high-value biotech stocks

Our new On the Radar report returns with fresh insights from Simos Simeonidis, PhD, Rodman & Renshaw's senior biotech analyst, who highlights biotech stocks which he believes will be good value

Celsion Announces Positive Interim Data Update from its Phase 2 DIGNITY Study in Breast Cancer

ThermoDox® Continues to Demonstrate Impressive Local Response Rate in Refractory Patients LAWRENCEVILLE, N.J., July 24, 2014 /PRNewswire/ -- Celsion Corporation CLSN +7.43% announced today...

Merck Initiates Phase 3 Study of Letermovir, an Investigational Antiviral for Prevention of Cytomegalovirus (CMV) Infection in High-Risk Bone Marrow Transplant Patients

WHITEHOUSE STATION, N.J., Jul 24, 2014 (BUSINESS WIRE) -- Merck MRK +0.10% , known as MSD outside the United States and Canada, today announced that the first patient has been enrolled in a global...

Biotech IPOs sputter amid downsizings, disappointments and white flags

Six biotechs were expected to go public this week, eyeing nearly $400 million combined, but that potential has so far amounted to one deeply discounted offering, one bottom-of-the-range debut and one outright cancelation.

Pfenex Inc. Announces Pricing Of Initial Public Offering

SAN DIEGO, July 24, 2014 -- Pfenex Inc. (NYSE MKT: PFNX) today announced the pricing of its initial public offering of 8,333,333 shares of its common stock at a price to the public of $6.00 per...

Immune Design Announces Pricing of Initial Public Offering

SEATTLE and SOUTH SAN FRANCISCO, Calif., July 24, 2014 -- Immune Design (IMDZ) announced today the pricing of its initial public offering of 5,000,000 shares of its common stock at a price of $12.00...

Merck launches PhIII antiviral drug study; Celsion buoyed by interim cancer data;

@FierceBiotech: We're looking for 2014's Fiercest women in biotech. More | Follow @FierceBiotech @JohnCFierce: Purdue earns a nod--and a quick slap--for abuse-resistant painkiller. News |...

Sarepta slips after new CSO is quickly pushed out

So what happened to Sarepta's ($SRPT) new chief scientific officer? Hired just 7 months ago, the biotech issued a one-liner in an 8-K this morning stating simply that Art Krieg had been "terminated."

Purdue earns a nod--and a quick slap--for abuse-resistant painkiller

The FDA has approved a new pain drug from Purdue Pharma that's intended to throw up a line of defense against the abuse of an extended-release reformulation of OxyContin. But all the approval seems to have accomplished is triggering some added eye-rolling from some of the experts fighting abuse.

Israel's Atox banks $23M to fight flesh-eating bacteria

Israeli drug developer Atox Bio has raised a $23 million E round to support its treatment for rare, tissue-destroying bacteria, paving the way for late-stage work.